Benzinga | May 26, 2021 12:13PM EDT

B. Riley Securities Downgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $18

B. Riley Securities analyst Mayank Mamtani downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Buy to Neutral and lowers the price target from $65 to $18.